India Story Tempered? Govt. May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments
Executive Summary
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
You may also be interested in...
India's Health Minister Hits Out At Buyouts By Foreign Drug Makers; Are Investment Restrictions In The Cards?
MUMBAI - India's health minister Ghulam Nabi Azad has reiterated his concerns about the growing dominance of multinational companies in the Indian market, pressing the commerce ministry to disallow full or majority ownership of Indian companies by large foreign drug makers
Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings